Table III.
Clinical and pathological characteristics of the patients with low/low-intermediate risk of endometrioid type endometrial cancer.
| Lymphadenectomy | |||
|---|---|---|---|
|
|
|||
| Variable | Pelvic, n=78 | Pelvic and para-aortic, n=41 | P-value |
| Median age at surgery, years (IQR) | 54 (48–59) | 50 (50–62) | 0.061 |
| Histologic subtype, N (%) | |||
| Endometrioid, pure | 57 (73.1) | 25 (61.0) | 0.180a |
| Endometrioid, with squamous differentiation | 19 (24.3) | 16 (39.0) | |
| Endometrioid, villoglandular variant | 1 (1.3) | 0 (0.0) | |
| Endometrioid, ciliated cell variant | 1 (1.3) | 0 (0.0) | |
| FIGO stage, n (%) | |||
| IA | 67 (85.9) | 26 (63.4) | <0.001b |
| IB | 11 (14.1) | 5 (12.2) | |
| II | 0 (0.0) | 10 (24.4) | |
| Grade, n (%) | |||
| I | 69 (88.5) | 34 (82.9) | 0.330b |
| II | 9 (11.5) | 6 (14.6) | |
| III | 0 (0.0) | 1 (2.5) | |
| Myometrial invasion, n (%) | |||
| <1/2 | 67 (85.9) | 31 (75.6) | 0.160 |
| ≥1/2 | 11 (14.1) | 10 (24.4) | |
| Lymphovascular invasion, n (%) | 2 (2.6) | 1 (2.4) | 0.970 |
| Median tumor size, cm (IQR) | 2.5 (1.0–3.5) | 3.0 (2.0–4.0) | 0.054 |
| Peritoneal cytology positive, n (%) | 0 (0.0) | 1 (2.4) | 0.350 |
| Surgery, n (%) | |||
| Laparoscopy | 26 (33.3) | 2 (4.9) | <0.001 |
| Laparotomy | 52 (66.7) | 39 (95.1) | |
| Median lymph nodes removed, n (IQR) | |||
| Pelvic lymph nodes | 22 (18–27) | 26 (21–31) | 0.080 |
| Para-aortic lymph nodes | 0 (0.0) | 15 (9–19) | <0.001 |
| Adjuvant treatment, n (%) | |||
| None | 62 (79.5) | 18 (43.9) | <0.001a |
| Radiotherapy alone | 16 (20.5) | 21 (51.1) | |
| Chemotherapy alone | 0 (0.0) | 0 (0.0) | |
| Chemotherapy and radiotherapy | 0 (0.0) | 1 (2.5) | |
| Unknown | 0 (0.0) | 1 (2.5) | |
| Median follow up time, months (95% CI) | 38 (36.91–46.81) | 36 (31.37–46.14) | 0.440 |
IQR, interquartile range; FIGO, International Federation of Gynaecology and Obstetrics; CI, confidence interval. P-values following the Bonferroni correction were a0.0125 and b0.0167.